...
首页> 外文期刊>Clinical & developmental immunology. >B Cell Activating Factor, Renal Allograft Antibody-Mediated Rejection, and Long-Term Outcome
【24h】

B Cell Activating Factor, Renal Allograft Antibody-Mediated Rejection, and Long-Term Outcome

机译:B细胞活化因子,肾同种异体移植抗体介导的抑制,以及长期结果

获取原文

摘要

Antibody-mediated rejection (ABMR) of renal allograft lacks typical phenotypes and clinical manifestations, always resulting in delayed diagnosis and treatment. It has been considered to be an elemental factor influencing the improvement of the long-term outcome of renal allograft. The B cell activating factor (BAFF) signal plays a fundamental function in the process of antibody-mediated immune response. Data from recipients and the nonhuman primate ABMR model suggest that the BAFF signal participates in the ABMR of renal allograft, while there are objections. The challenges in the diagnosis of ABMR, different study population, and details of research may explain the discrepancy. Large quantities of dynamic, credible data of BAFF ligands and their association with renal allograft pathological characteristics would constitute a direct proof of the role of BAFF in the progression of renal allograft ABMR.
机译:抗体介导的肾异种移植物的抑制(ABMR)缺乏典型的表型和临床表现,始终导致诊断和治疗延迟。它被认为是影响肾同种异体移植的长期结果的基本因素。 B细胞活化因子(BAFF)信号在抗体介导的免疫应答过程中起着基本功能。来自收件人的数据和非人类灵长类动物ABMR模型表明,BAFF信号参与肾同种异体移植物的ABMR,而存在异议。诊断ABMR,不同的学习人口和研究细节的挑战可以解释差异。 BAFF配体的大量动态,可信数据及其与肾同种异体移植病理特征的关联将构成诸如肾同种异体移植ABMR进展中的诸如BAFF的作用的直接证明。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号